Clinical Trials Logo

Myopia Progression clinical trials

View clinical trials related to Myopia Progression.

Filter by:

NCT ID: NCT06265454 Not yet recruiting - Myopia Progression Clinical Trials

Low Dose Atropine Eye Drops in Myopic Egyptian Children

LAMP
Start date: September 1, 2024
Phase: Phase 2
Study type: Interventional

Previous Studies reported that low concentration atropine eye drops may be effective in increasing the choroidal blood flow and thickness and this slows myopia progression. purpose of the study is to compare changes in axial length, anterior chamber depth, choroidal thickness, central corneal thickness and anterior scleral thickness among myopic children receiving atropine 0.05% or 0.01% and placebo.

NCT ID: NCT06034327 Recruiting - Myopia Clinical Trials

Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens

EUCALYPTUS
Start date: September 18, 2023
Phase: N/A
Study type: Interventional

This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy. This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.

NCT ID: NCT05893979 Active, not recruiting - Myopia Clinical Trials

Myopia Control Spectacle Lens Cessation Study

BIRCH
Start date: June 23, 2023
Phase: N/A
Study type: Interventional

To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses. To quantify axial length progression following cessation of use of specific spectacle lenses.

NCT ID: NCT05700240 Completed - Myopia Progression Clinical Trials

Effect of Orthokeratology on Myopia Progression in French Children

Start date: November 2, 2019
Phase:
Study type: Observational

To evaluate and to compare the effect of orthokeratology (OK) on axial elongation in French myopic children.

NCT ID: NCT05650190 Completed - Myopia Clinical Trials

Spectacle Lens Visual Acuity Assessments Study

CEDAR
Start date: December 8, 2022
Phase: N/A
Study type: Interventional

This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.

NCT ID: NCT05617794 Active, not recruiting - Myopia Clinical Trials

Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness

ASH-2
Start date: January 18, 2023
Phase: N/A
Study type: Interventional

The objective of the study is to measure the effect of Diffusion Optics Technology (DOT) spectacle lenses on the choroidal thickness and choroidal vascularity index compared to control lenses.

NCT ID: NCT03952702 Active, not recruiting - Clinical trials for Intermittent Exotropia

Overminus Lens Therapy in Intermittent

Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

In this prospective study, entitled "The Long-Term Efficacy of Overminus Lens Therapy in Intermittent Exotropia",the investigators examined the long-term impact of overminus lenses on the management of intermittent exotropia (IXT), treatment effect after overminus treatment has been discontinued and also investigated if overminus lenses cause myopia in long-term.

NCT ID: NCT03381079 Not yet recruiting - High Myopia Clinical Trials

Efficacy and Safety of Posterior Scleral Reinforcement on Controlling Myopia in Adults With High Myopia

Start date: April 1, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of posterior scleral reinforcement on controlling myopia progression, including change in refraction, axial elongation as well as sight-threatening complications, in adults with high myopia. Half the adults will receive posterior scleral reinforcement, while the other half will receive no surgerical treatment.

NCT ID: NCT02623543 Recruiting - Myopia Progression Clinical Trials

Effectiveness of Orthokeratology in Decreasing Myopic Progression in a Young Adult Population Enrolled in a Professional Optometric Curriculum

Start date: November 2013
Phase: Phase 2
Study type: Interventional

The high prevalence of myopia - especially in Asian countries - is well documented, as are the sight-threatening complications of high or degenerative myopia. Retinal detachment, glaucoma, vitreal degeneration and focal retinal changes occur secondary to the progressive axial elongation of the eye with age. Specialty rigid lenses have long been shown to lessen this progression in the pediatric population; orthokeratology (ortho-k) lenses are worn at night and change the corneal topography to correct low to moderate amounts of myopia. This same axial elongation has also been shown to occur in young adults with high near demands, however to our knowledge, there are no studies examining the effect of ortho-k lenses in this population. Our project seeks to investigate the efficacy of ortho-k in slowing axial elongation and myopic progression in subjects between the ages of 21-30. Results will help elucidate what role these specialty lenses may have in the management of the myopic patient throughout their development, as well as what potential they have in prevention of associated degenerative changes.

NCT ID: NCT02130167 Completed - Myopia Progression Clinical Trials

Low Concentration Atropine for Myopia Progression in School Children

Start date: August 2012
Phase: N/A
Study type: Interventional

Myopia is the leading cause of blindness in Taiwan. The younger children with myopia, the higher risk of high myopia in later life and complications such as retinal detachment and maculopathy will occur. We have reported the low concentration of atropine (0.05%) with the effect on retarding the myopia progression. Recently the 0.01% atropine was also reported effective and with less visual side effects such as mydriasis. The aim of this study is to compare the efficacy in controlling myopia progression and visual side effects of 2 low concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.